Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy

Publisher： Bentham Science Publishers

E-ISSN： 1996-3181|15|8|945-955

ISSN： 1871-5273

Source： CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol.15, Iss.8, 2016-09, pp. : 945-955

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents

By  

Current Cancer Drug Targets, Vol. 4, Iss. 8, 2004-12 ,pp. : 621-635

Bentham Science Publishers

Access to resources Recommend Favorite

Mammalian Target of Rapamycin (mTOR) Inhibitors: Potential Uses and a Review of Haematological Adverse Effects

By Sofroniadou Sofia   Goldsmith David  

Drug Safety, Vol. 34, Iss. 2, 2011-02 ,pp. : 97-115

Adis International

Access to resources Recommend Favorite

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer

By Albert Sébastien   Serova Maria   Dreyer Chantal   Sablin Marie-Paule   Faivre Sandrine   Raymond Eric  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 8, 2010-08 ,pp. : 919-930

Informa Healthcare

Access to resources Recommend Favorite

mTOR pathway inhibitors in cancer therapy: moving past rapamycin

By Wacheck Volker  

Pharmacogenomics, Vol. 11, Iss. 9, 2010-09 ,pp. : 1189-1191

Future Medicine

Access to resources Recommend Favorite

Current and future directions in mammalian target of rapamycin inhibitors development

By Fasolo Angelica   Sessa Cristiana  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 3, 2011-03 ,pp. : 381-394

Informa Healthcare

Access to resources Recommend Favorite